Previous 10 | Next 10 |
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on nex...
Additional data from a phase 3 trial of Aeglea BioTherapuetics' (NASDAQ:AGLE) pegzilarginase for the rare inherited metabolic disorder Arginase 1 Deficiency (ARG1-D) sent shares surging 40% in after-hours trading. In a patient-level outcomes analysis, 11 patients (65%) receiving peg...
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD PR Newswire AUSTIN, Texas , April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical...
Gainers: Aeglea BioTherapeutics (AGLE) +10%. Gossamer Bio (GOSS) +8%. Resources Connection (RGP) +7%. Conn's (CONN) +6%. Pixelworks (PXLW) +5%. Losers: Qorvo (QRVO) -7%. SoFi Technologies (SOFI) -5%. Deciphera Pharmaceuticals (DCPH) -5%. Oxford Lane Capital (OXL...
Shares of Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) traded today at $12.80, eclipsing its 52-week high. Approximately 14.4 million shares have changed hands today, as compared to an average 30-day volume of 349,000 shares. Aeglea BioTherapeutics Inc is a clinical-stage biotechnology comp...
Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022 PR Newswire AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting PR Newswire AUSTIN, Texas , March 29, 2022 ...
Aeglea BioTherapeutics press release (NASDAQ:AGLE): FY GAAP EPS of -$1.00 beats by $0.02. Revenue of $18.73M beats by $1.33M. As of December 31, 2021, the company had available cash, cash equivalents, marketable securities and restricted cash of $95.0 million For further details see: Ae...
Aeglea BioTherapeutics (AGLE -6.5%) is trading lower for the third straight session after announcing that Sara Brownstein, a Class I director of its Board, informed the company on Wednesday that she would resign, effective Feb. 09. “The Company believes Ms. Brownstein’s resignat...
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...